Pyrazolo[4,3-d]pyrimidines as new generation of cyclin-dependent kinase inhibitors
Language English Country Great Britain, England Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
12941318
DOI
10.1016/s0960-894x(03)00631-0
PII: S0960894X03006310
Knihovny.cz E-resources
- MeSH
- Cell Division drug effects MeSH
- K562 Cells MeSH
- Cyclin B antagonists & inhibitors MeSH
- Cyclin-Dependent Kinases antagonists & inhibitors MeSH
- Inhibitory Concentration 50 MeSH
- Enzyme Inhibitors chemistry pharmacology MeSH
- Humans MeSH
- CDC2 Protein Kinase antagonists & inhibitors MeSH
- Antineoplastic Agents chemistry pharmacology MeSH
- Pyrazoles chemistry pharmacology MeSH
- Pyrimidines chemistry pharmacology MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Cyclin B MeSH
- Cyclin-Dependent Kinases MeSH
- Enzyme Inhibitors MeSH
- CDC2 Protein Kinase MeSH
- Antineoplastic Agents MeSH
- pyrazolo(3,4-d)pyrimidine MeSH Browser
- Pyrazoles MeSH
- Pyrimidines MeSH
A search among analogues of anti-CDK purines led to the identification of substituted pyrazolo[4,3-d]pyrimidines as novel inhibitors of CDK1/cyclin B. Some of these derivatives also show antiproliferative activity on cancer cell line K-562, thus may find an application as anticancer agents.
References provided by Crossref.org
